Bringing a new drug to market costs over one billion dollars. For the consumer, this can mean fewer medicines in development, and for pharmaceutical companies it results in limited time to recoup costs before their patents expire. Curtin chemical engineering researchers have developed a patented manufacturing platform for the production of targeted drug delivery systems. ARISE, or Atomised Rapid Injection for Solvent Extraction, is a multifunctional platform that produces customisable micron and sub-micron particles of active ingredients, that can also be ‘coated’, if required. Smaller particles are more readily absorbed, and also more effectively inhaled. The ability to ‘coat’ the ingredients, for example, to protect them as they journey through the stomach can enhance the treatment of colon diseases. ARISE is a technology that delivers more medicine to where it is needed. This can lead to lower dosages, reduced side-effects, improved patient compliance and, ultimately, more effective treatments. It can extend product lifecycles through reformulating existing drugs, providing alternative delivery systems, and repurposing medicines for new indications. The ARISE platform has been proven at lab scale, and work has commenced on a scale-up demonstration plant. ARISE meets the challenges faced by pharmaceutical companies by creating the opportunity to fully realise their return on investment in drug research and development.